Quantum Biopharma Ltd. Class B Subordinate Voting Shares (QNTM)
NASDAQ: QNTMHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
QNTM stock chart
Technical analysisKey statistics
All statistics- Market cap
- $8.29M
- EPS (TTM)
- -$3.42
- Dividend yield
- None
- 52-week range
- 1.26 – 12.42
- Day range
- 1.26 – 1.41
- Volume / Avg
- 140.26K / 148.83K
- Beta
- —
- Shares outstanding
- 6.43M
52-week range
QNTM stock today
Shares of Quantum Biopharma (QNTM) finished lower on Nov 20 at $1.29, a drop of 9.15% or $0.13 per share, versus the S&P 500's 3.70% decline. At this level, QNTM sits near the bottom of its 52-week range of $1.26 to $12.42: 89.6% below the high, set on Nov 28, 2025 and 2.4% above the low. QNTM is down 82.3% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 77.6%.
Quantum Biopharma has posted a net loss over the last twelve months (EPS of -$3.42), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Quantum Biopharma
Company profileQuantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. The company operates through two segments, Biopharmaceutical Innovation and Strategic Investments. It researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Zeeshan Saeed
- Headquarters
- Toronto, ON
- Website
- quantumbiopharma.com
Financial highlights
Full financials| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | — | — | — | $-23.61M | $-35.29M |
| EPS (diluted) | — | — | — | — | — |
Analyst forecast
ForecastConsensus
none
Avg. price target
$12.27+851.16%
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-0.06 vs —
QNTM news
All QNTM news- Quantum BioPharma achieve 91% increase in Shareholder Equity and Liquidity in Q3 2026 as Lucid-MS Phase 2 Trial Advances into Study Start-UpGlobeNewswire
- Quantum BioPharma Announces Results of Annual General and Special Meeting of Shareholders and Closing of Private Placement of Class A Multiple Voting SharesGlobeNewswire
- Quantum BioPharma Ltd. Announces Filing of Supplement to Management Information Circular Correcting Fractional Share Treatment Under Proposed Share Consolidation and Clarifies MVS Voting Power ThresholdGlobeNewswire
- Quantum BioPharma (NASDAQ: QNTM) Draws ‘Men’s Fitness’ Spotlight as Unbuzzd Trial Shows Early PromiseBusiness Insider
- Quantum BioPharma’s Phase 2 Shows Where Biotech Value Actually Gets BuiltNasdaqQNTM, TMO
- World Renowned Law Firm Grant & Eisenhofer Appointed Lead Counsel In Newly Consolidated Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma SharesGlobeNewswire
Quantum Biopharma peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| MBRXMoleculin Biotech Inc. | 7.74 | -2.40% | $8.22M | vs QNTM |
| HINDVyome Holdings Inc. | 1.20 | -17.24% | $8.42M | vs QNTM |
| PTNPalatin Technologies Inc. | 4.58 | -7.10% | $8.16M | vs QNTM |
| LEXXLexaria Bioscience Corp. | 4.03 | -10.24% | $8.49M | vs QNTM |
| DAREDare Bioscience Inc. | 0.4074 | -9.87% | $8.01M | vs QNTM |
| BIVIBioVie Inc. Class A | 0.80 | -12.07% | $8.58M | vs QNTM |
| CLRBCellectar Biosciences Inc. | 0.797 | -11.50% | $8.00M | vs QNTM |
| OPTHOptimi Health Corp. | 1.51 | -13.71% | $8.65M | vs QNTM |
Indexes, lists and sector
Quantum Biopharma stock FAQ
What is Quantum Biopharma's stock price today?
QNTM last traded at $1.29 as of Nov 20, 4:00 PM EST, down 9.15% on the day. Prices are delayed at least 15 minutes.
Does Quantum Biopharma pay a dividend?
No. Quantum Biopharma does not currently pay a regular cash dividend.
Who is Quantum Biopharma's CEO?
Mr. Zeeshan Saeed is the chief executive officer of Quantum Biopharma Ltd. Class B Subordinate Voting Shares.
Has QNTM ever split its stock?
Yes. The most recent QNTM stock split was a 1-for-65 split on Aug 15, 2024, one of 2 splits on record.
What is the QNTM 52-week high?
The 52-week high for QNTM is $12.42 and the 52-week low is $1.26. The stock is currently 89.6% below its high.